Rani Therapeutics Secures $4.3M via Series D Warrant

The latest announcement is out from Rani Therapeutics Holdings ( (RANI) ).

On May 20, 2025, Rani Therapeutics Holdings entered into a letter agreement with an institutional investor to issue a new Series D common stock warrant and adjust the exercise prices of existing Series B and C warrants. This agreement, expected to close on May 21, 2025, will generate approximately $4.3 million in gross proceeds for Rani Therapeutics, which plans to use the funds for working capital and general corporate purposes. The company will seek stockholder approval for the Series D warrant and file a resale registration with the SEC. Maxim Group LLC acted as the financial advisor for the transaction.

The most recent analyst rating on (RANI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.

Spark’s Take on RANI Stock

According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.

Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.

To see Spark’s full report on RANI stock, click here.

More about Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative oral biologics. The company is known for its proprietary technology that enables the oral delivery of biologic drugs, which traditionally require injection, aiming to improve patient compliance and expand the market for biologic therapies.

Average Trading Volume: 389,888

Technical Sentiment Signal: Sell

Current Market Cap: $40.28M

Learn more about RANI stock on TipRanks’ Stock Analysis page.